Document:

Subscription Agreement

 Exhibit 10.1 
  
 SUBSCRIPTION AGREEMENT 
  

THIS SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of May 27, 2004, by and among Commonwealth Biotechnologies, Inc., a Virginia
corporation (the “Company”), and the subscribers identified on the signature page hereto (each a “Subscriber” and collectively “Subscribers”). 
  
 WHEREAS, the Company and the Subscribers are executing and delivering this Agreement in reliance upon an exemption
from securities registration afforded by the provisions of Section 4(2), Section 4(6) and/or Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “Commission”) under the
Securities Act of 1933, as amended (the “1933 Act”). 
  
 WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to the Subscribers, as provided herein, and the Subscribers shall purchase, in the aggregate,
$2,500,000 (the “Purchase Price”) of the Company’s common stock, no par value (the “Common Stock” or “Shares”), and share purchase warrants in the form attached hereto as Exhibit A (the
“Warrants”), to purchase shares of Common Stock (the “Warrant Shares”). The Purchase Price shall be payable to the Company on the Closing Date, as defined in Section 13(b) hereof. The Common Stock, the Warrants and the Warrant
Shares are collectively referred to herein as the “Securities”; and 
  
 WHEREAS, the aggregate proceeds of the sale of the Common Stock and the Warrants contemplated hereby shall be held in escrow pursuant to the terms of a Funds Escrow Agreement to be executed by the parties
substantially in the form attached hereto as Exhibit B (the “Escrow Agreement”). 
  
 NOW, THEREFORE, in consideration of the mutual covenants and other agreements contained in this Agreement the Company and the Subscribers hereby
agree as follows: 
  
 1. Purchase and Sale of Shares and
Warrants. Subject to the satisfaction (or waiver) of the conditions to Closing set forth in this Agreement and the Escrow Agreement, each Subscriber shall purchase the Shares and Warrants for the portion of the Purchase Price indicated on the
signature page hereto, and the Company shall sell such Shares and Warrants to the Subscriber. The Purchase Price for the Shares and Warrants shall be paid in cash. The entire Purchase Price shall be allocated to the Shares. The Purchase Price for
each Share shall equal the greater of (i) $6.25, or (ii) 80% of the value weighted average price for the five trading days immediately preceding the Closing. 
  
 2. Escrow Arrangements; Form of Payment. Upon execution hereof by the parties and pursuant to the terms of the Escrow Agreement, each Subscriber
agrees to make the deliveries required of such Subscriber as set forth in the Escrow Agreement and the Company agrees to make the deliveries required of the Company as set forth in the Escrow Agreement. 
  
 3. Warrants. On the Closing Date, the Company will issue Warrants to
the Subscribers. One (1) Warrant will be issued for each four (4) Shares issued on the Closing Date. The exercise price for each Share issuable upon exercise of a Warrant shall be 110% of the closing price of the Common Stock on the Closing Date.
The Warrants shall be exercisable for a period of five (5) years from the Closing Date. 

 4. Subscriber’s Representations and Warranties. Each Subscriber hereby represents and
warrants to and agrees with the Company only as to such Subscriber that: 
  
 (a) Information on Company. The Subscriber has been furnished with or has had access at the EDGAR Website of the Commission to the Company’s Form 10-KSB for the year ended December 31, 2003 as filed with
the Commission, together with all subsequently filed Forms 10-QSB, 8-K, and filings made with the Commission available at the EDGAR website (hereinafter referred to collectively as the “Reports”). In addition, the Subscriber has received
in writing from the Company such other information concerning its operations, financial condition and other matters as the Subscriber has requested in writing (such other information is collectively, the “Other Written Information”), and
considered all factors the Subscriber in its sole discretion deems material in deciding on the advisability of investing in the Securities. 
  
 (b) Information on Subscriber. The Subscriber is, and will be at the Closing Date and time of exercise of any of the Warrants, an “accredited
investor”, as such term is defined in Regulation D promulgated by the Commission under the 1933 Act, is experienced in investments and business matters, has made investments of a speculative nature and has purchased securities of United States
publicly-owned companies in private placements in the past and, with its representatives, has such knowledge and experience in financial, tax and other business matters as to enable the Subscriber to utilize the information made available by the
Company to evaluate the merits and risks of and to make an informed investment decision with respect to the proposed purchase, which represents a speculative investment. The Subscriber has the authority and is duly and legally qualified to purchase
and own the Securities. The Subscriber is able to bear the risk of such investment for an indefinite period and to afford a complete loss thereof. The information set forth on the signature page hereto regarding the Subscriber is accurate.

  
 (c) Purchase of Common Stock and Warrants. On the
Closing Date, the Subscriber will purchase the Common Stock and Warrants as principal for its own account and not with a view to any distribution thereof. 
  
 (d) Compliance with Securities Act. The Subscriber understands and agrees that the Securities have not been registered under the 1933 Act or any
applicable state securities laws, by reason of their issuance in a transaction that does not require registration under the 1933 Act (based in part on the accuracy of the representations and warranties of Subscriber contained herein), and that such
Securities must be held indefinitely unless a subsequent disposition is registered under the 1933 Act or any applicable state securities laws or is exempt from such registration. In any event, and subject to compliance with applicable securities
laws, the Subscriber may enter into hedging transactions with third parties, which may in turn engage in short sales of the Securities in the course of hedging the position they assume and the Subscriber may also enter into short positions or other
derivative transactions relating to the Securities, or interests in the Securities, and deliver the Securities, or interests in the Securities, to close out their short or other positions or otherwise settle short sales or other transactions, or
loan or pledge the Securities, or interests in the Securities, to third parties that in turn may dispose of these Securities. 
  
 (e) Shares Legend. The Shares and the Warrant Shares shall bear the following or similar legend: 
  
 “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THESE SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAW OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO COMMONWEALTH BIOTECHNOLOGIES, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.” 
  

 2 

 (f) Warrants Legend. The Warrants shall bear the following or similar legend: 
  
 “THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS
WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT OR ANY APPLICABLE STATE SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO COMMONWEALTH BIOTECHNOLOGIES, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.” 
  
 (g) Communication of Offer. The offer to sell the Securities was
directly communicated to the Subscriber by the Company. At no time was the Subscriber presented with or solicited by any leaflet, newspaper or magazine article, radio or television advertisement, or any other form of general advertising or solicited
or invited to attend a promotional meeting otherwise than in connection and concurrently with such communicated offer. 
  
 (h) Authority; Enforceability. This Agreement and other agreements delivered together with this Agreement or in connection herewith have been duly
authorized, executed and delivered by the Subscriber and are valid and binding agreements enforceable in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general
applicability relating to or affecting creditors’ rights generally and to general principles of equity; and Subscriber has full corporate power and authority necessary to enter into this Agreement and such other agreements and to perform its
obligations hereunder and under all other agreements entered into by the Subscriber relating hereto. 
  
 (i) Correctness of Representations. Each Subscriber represents as to such Subscriber that the foregoing representations and warranties are true
and correct as of the date hereof and, unless a Subscriber otherwise notifies the Company prior to the Closing Date (as hereinafter defined), shall be true and correct as of the Closing Date. 
  
 (j) Survival. The foregoing representations and warranties shall
survive the Closing Date for a period of two years. 
  
 5.
Company Representations and Warranties. The Company represents and warrants to and agrees with each Subscriber that: 
  
 (a) Due Incorporation. The Company is a corporation duly organized, validly existing and in good standing under the laws of the Commonwealth of
Virginia and has the requisite corporate power to own its properties and to carry on its business as now being conducted. The Company is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the
nature of the business conducted or property owned by it makes such qualification necessary, other than those jurisdictions in which the failure to so qualify would not have a material adverse effect on the business, operations or financial
condition of the Company. 
  

 3 

 (b) Outstanding Stock. All issued and outstanding shares of capital stock of the Company has been
duly authorized and validly issued and are fully paid and non-assessable. 
  
 (c) Authority; Enforceability. This Agreement, the Common Stock, the Warrants, the Escrow Agreement and any other agreements delivered together with this Agreement or in connection herewith (collectively
“Transaction Documents”) have been duly authorized, executed and delivered by the Company and are valid and binding agreements enforceable in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights generally and to general principles of equity. The Company has full corporate power and authority necessary to enter into and
deliver the Transaction Documents and to perform its obligations thereunder. 
  
 (d) Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s Common Stock or equity and no outstanding rights, warrants or options to acquire, or
instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of Common Stock or equity of the Company except as described on Schedule 5(d), or the Reports.

  
 (e) Consents. No consent, approval, authorization or
order of any court, governmental agency or body or arbitrator having jurisdiction over the Company, or any of its affiliates, the Nasdaq Small Cap Market (the “Principal Market”) nor the Company’s shareholders is required for the
execution by the Company of the Transaction Documents and compliance and performance by the Company of its obligations under the Transaction Documents, including, without limitation, the issuance and sale of the Securities. 
  
 (f) No Violation or Conflict. Assuming the representations and
warranties of the Subscribers in Section 4 are true and correct, neither the issuance and sale of the Securities nor the performance of the Company’s obligations under the Transaction Documents will: 
  
 (i) violate, conflict with, result in a breach of, or constitute a default
(or an event which with the giving of notice or the lapse of time or both would be reasonably likely to constitute a default) under (A) the articles of incorporation or bylaws of the Company, (B) to the Company’s knowledge, any decree,
judgment, order, law, treaty, rule, regulation or determination applicable to the Company of any court, governmental agency or body, or arbitrator having jurisdiction over the Company or over the properties or assets of the Company or any of its
affiliates, (C) the material terms of any bond, debenture, note or any other evidence of indebtedness, or any agreement, stock option or other similar plan, indenture, lease, mortgage, deed of trust or other instrument to which the Company is a
party, by which the Company is bound, or to which any of the properties of the Company is subject, except the violation, conflict, breach, or default of which would not have a material adverse effect on the Company, or (D) the terms of any
“lock-up” or similar provision of any underwriting or similar agreement to which the Company, or any of its affiliates is a party except the violation, conflict, breach, or default of which would not have a material adverse effect on the
Company; or 
  
 (ii) result in the creation or imposition of any
lien, charge or encumbrance upon the Securities or any of the assets of the Company except where such would not have a material adverse effect on the Company ; or 
  

 4 

 (iii) result in the activation of any anti-dilution rights or a reset or repricing of any debt or
security instrument of any other creditor or equity holder of the Company, nor result in the acceleration of the due date of any obligation of the Company; or 
  

(iv) result in the activation of any piggy-back registration rights of any person or entity holding securities of the Company or having the right to
receive securities of the Company. 
  
 (g) The
Securities. The Securities upon issuance: 
  
 (i) are, or
will be, free and clear of any security interests, liens, claims or other encumbrances, subject to restrictions upon transfer under the 1933 Act and any applicable state securities laws; 
  
 (ii) have been, or will be, duly and validly authorized and on the date of issuance of the Shares and upon exercise of the
Warrants, the Shares and Warrant Shares will be duly and validly issued, fully paid and nonassessable (and if registered pursuant to the 1933 Act, and resold pursuant to an effective registration statement will be free trading and unrestricted,
provided that each Subscriber complies with the prospectus delivery requirements of the 1933 Act); 
  
 (iii) will not have been issued or sold in violation of any preemptive or other similar rights of the holders of any securities of the Company; and

  
 (iv) will not subject the holders thereof to personal
liability by reason of being such holders. 
  
 (h)
Litigation. There is no pending or, to the best knowledge of the Company, threatened action, suit, proceeding or investigation before any court, governmental agency or body, or arbitrator having jurisdiction over the Company, or any of its
affiliates that would affect the execution by the Company or the performance by the Company of its obligations under this Agreement, and all other agreements entered into by the Company relating hereto. Except as disclosed in the Reports, there is
no pending or, to the best knowledge of the Company, threatened action, suit, proceeding or investigation before any court, governmental agency or body, or arbitrator having jurisdiction over the Company, or any of its affiliates which litigation if
adversely determined could have a material adverse effect on the Company, nor is there, to the best knowledge of the Company, any basis for any such action, suit, proceedings or investigation. 
  
 (i) Reporting Company. The Company is a publicly-held company subject
to reporting obligations pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “1934 Act”) and has a class of common shares registered pursuant to Section 12(b) of the 1934 Act. Pursuant to the provisions of the
1934 Act, the Company has timely filed all reports and other materials required to be filed thereunder with the Commission during the preceding twelve months. 
  

(j) No Market Manipulation. The Company has not taken, and will not take, directly or indirectly, any action designed to, or that might
reasonably be expected to, cause or result in stabilization or manipulation of the price of the common stock of the Company to facilitate the sale or resale of the Securities or affect the price at which the Securities may be issued or resold.

  
 (k) Information Concerning Company. The Reports
contain all material information relating to the Company and its operations and financial condition as of their respective dates which information is required to be disclosed therein. Since the date of the financial statements included 

 

 5 

 in the Reports, and except as modified in the Other Written Information or in the Schedules hereto, there has been no
material adverse change in the Company’s business, financial condition or affairs not disclosed in the Reports. The Reports do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading in light of the circumstances when made. 
  
 (l) Stop Transfer. The Securities, when issued, will be restricted securities. The Company will not issue any stop transfer order or other order
impeding the sale, resale or delivery of any of the Securities, except as may be required by any applicable federal or state securities laws and unless contemporaneous notice of such instruction is given to the Subscriber. 
  
 (m) Defaults. The Company is not in violation of its articles of
incorporation or bylaws. The Company is (i) not in default under or in violation of any other material agreement or instrument to which it is a party or by which it or any of its properties are bound or affected, which default or violation would
have a material adverse effect on the Company, (ii) not in default with respect to any order of any court, arbitrator or governmental body or subject to or party to any order of any court or governmental authority arising out of any action, suit or
proceeding under any statute or other law respecting antitrust, monopoly, restraint of trade, unfair competition or similar matters, or (iii) to its knowledge not in violation of any statute, rule or regulation of any governmental authority which
violation would have a material adverse effect on the Company. In addition, it is acknowledged by the parties hereto that the Company shall file copies of this Agreement, the Warrants and the Placement Agent Warrant as material contracts in its
filings with the Securities and Exchange Commission. 
  
 (n)
No Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales of any security or solicited any offers to buy any security under
circumstances that would cause the offer of the Securities pursuant to this Agreement to be integrated with prior offerings by the Company for purposes of the 1933 Act or any applicable stockholder approval provisions, including, without limitation,
under the rules and regulations of the Principal Market. Nor will the Company take any action or steps that would cause the offer of the Securities to be integrated with other offerings. The Company will not conduct any offering other than the
transactions contemplated hereby that will be integrated with the offer or issuance of the Securities. 
  
 (o) No General Solicitation. Neither the Company, nor any of its affiliates, nor to its knowledge, any person acting on its or their behalf, has
engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the 1933 Act) in connection with the offer or sale of the Securities. 
  
 (p) Listing. The Company’s common stock is listed on the Principal Market. The Company has not received any
oral or written notice that its Common Stock will be delisted or become ineligible for continued listing quotation on The Principal Market, other than certain notices previously received from the Principal Market that have since been rescinded by
the Principal Market 
  
 (q) No Undisclosed Liabilities.
The Company has no liabilities or obligations which are material, individually or in the aggregate, which are not disclosed in the Reports and Other Written Information, other than those incurred in the ordinary course of the Company’s
businesses since December 31, 2003 and which, individually or in the aggregate, would reasonably be expected to have a material adverse effect on the Company’s financial condition. 
  

 6 

 (r) No Undisclosed Events or Circumstances. Since December 31, 2003, no event or circumstance has
occurred or exists with respect to the Company or its businesses, properties, operations or financial condition, that, under applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but
which has not been so publicly announced or disclosed in the Reports. 
  
 (s) Capitalization. The authorized and outstanding capital stock of the Company as of the date of this Agreement and the Closing Date are set forth on Schedule 5(s). Except as set forth in the Reports and Other Written
Information and Schedule 5(d), there are no options, warrants, or rights to subscribe to, securities, rights or obligations convertible into or exchangeable for or giving any right to subscribe for any shares of capital stock of the
Company. All of the outstanding shares of Common Stock of the Company have been duly and validly authorized and issued and are fully paid and nonassessable. 
  
 (t) Dilution. The Company’s executive officers and directors understand the nature of the Securities being sold hereby and recognize that the
issuance of the Securities will have a potential dilutive effect on the equity holdings of other holders of the Company’s equity or rights to receive equity of the Company. The board of directors of the Company has concluded, in its good faith
business judgment, that the issuance of the Securities is in the best interests of the Company. The Company specifically acknowledges that its obligation to issue the Securities is binding upon the Company and enforceable regardless of the dilution
such issuance may have on the ownership interests of other shareholders of the Company or parties entitled to receive equity of the Company. 
  
 (u) No Disagreements with Accountants and Lawyers. There are no disagreements of any kind presently existing, or reasonably anticipated by the
Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company, including but not limited to disputes or conflicts over payment owed to such accountants and lawyers. 
  
 (v) Investment Company. The Company is not, and is not an Affiliate
(as defined in Rule 405 under the 1933 Act) of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 
  
 (w) Correctness of Representations. The Company represents that the foregoing representations and warranties are true and correct as of the date
hereof in all material respects, and, unless the Company otherwise notifies the Subscribers prior to the Closing Date, shall be true and correct in all material respects as of the Closing Date. 
  
 (x) Patriot Act. The Company certifies that, to the best of
Company’s knowledge, the Company has not been designated, and is not owned or controlled, by a “suspected terrorist” as defined in Executive Order 13224. The Company hereby acknowledges that each Subscriber seeks to comply with all
applicable laws concerning money laundering and related activities. In furtherance of those efforts, the Company hereby represents, warrants and agrees that: (i) none of the cash or property that the Company will pay or will contribute to the
Subscriber has been or shall be derived from, or related to, any activity that is deemed criminal under United States law; and (ii) no contribution or payment by the Company to the Subscriber, to the extent that they are within the Company’s
control shall cause the Purchaser to be in violation of the United States Bank Secrecy Act, the United States International Money Laundering Control Act of 1986 or the United States International Money Laundering Abatement and Anti-Terrorist
Financing Act of 2001. The Company shall promptly notify the Subscriber if any of these representations ceases to be true and accurate regarding the Company. The Company agrees to provide the Subscriber any additional information regarding the
Company that the Subscriber deems necessary or convenient to ensure compliance with all applicable laws 
  

 7 

 concerning money laundering and similar activities. The Company understands and agrees that if at any time it is
discovered that any of the foregoing representations are incorrect, or if otherwise required by applicable law or regulation related to money laundering similar activities, the Subscriber may undertake appropriate actions to ensure compliance with
applicable law or regulation, including but not limited to segregation and/or redemption of the Purchaser’s investment in the Company. The Company further understands that the Purchaser may release confidential information about the Company
and, if applicable, any underlying beneficial owners, to proper authorities if the Subscriber, in its sole discretion, determines that it is in the best interests of the Subscriber in light of relevant rules and regulations under the laws set forth
in subsection (ii) above. 
  
 (y) Survival. The foregoing
representations and warranties shall survive the Closing Date for a period of two years. 
  
 6. Regulation D Offering. The offer and issuance of the Securities to the Subscribers is being made pursuant to the exemption from the registration provisions of the 1933 Act afforded by Section 4(2) or Section
4(6) of the 1933 Act and/or Rule 506 of Regulation D promulgated thereunder. On the Closing Date, the Company will provide an opinion reasonably acceptable to Subscriber from the Company’s legal counsel opining on the availability of an
exemption from registration under the 1933 Act as it relates to the offer and issuance of the Securities and other matters reasonably requested by Subscribers. A form of the legal opinion is annexed hereto as Exhibit C. The Company will
provide, at the Company’s expense, such other legal opinions in the future as are reasonably necessary for the resale of the Common Stock and exercise of the Warrants and resale of the Warrant Shares. 
  
 7. Legal Fees. The Company shall pay to Sichenzia Ross Friedman
Ference LLP, a fee of $20,000 (“Legal Fees”) as reimbursement for services rendered to the Subscribers in connection with this Agreement and the purchase and sale of the Shares and Warrants (the “Offering”) and acting as Escrow
Agent for the Offering. The Legal Fees not previously paid will be payable on the Closing Date out of funds held pursuant to the Escrow Agreement. 
  
 8. Placement Agent. 
  
 (a) Placement -Agent’s Fee. The Company, on the one hand, and each Subscriber (for himself only) on the other hand, agree to indemnify
the other against and hold the other harmless from any and all liabilities to any persons claiming brokerage commissions, placement fees or finder’s fees other than Jesup & Lamont Securities Corp. (“Placement Agent”) on account of
services purported to have been rendered on behalf of the indemnifying party in connection with this Agreement or the transactions contemplated hereby and arising out of such party’s actions. Anything to the contrary in this Agreement
notwithstanding, each Subscriber is providing indemnification only for such Subscriber’s own actions and not for any action of any other Subscriber. Each Subscriber’s liability hereunder is several and not joint. The Company agrees that it
will pay the Placement Agent a cash fee equal to six percent (6%) of the Purchase Price directly out of the funds held pursuant to the Escrow Agreement. The Company represents that there are no other parties entitled to receive fees, commissions, or
similar payments in connection with the Offering except the Placement Agent. The Placement Agent will also be paid by the Company six percent (6%) of the cash proceeds received by the Company from any Warrant exercise (“Warrant Exercise
Compensation”). The Warrant Exercise Compensation must be paid by the Company to the Placement Agent within five (5) days after each receipt by the Company of Warrant Exercise cash proceeds. 
  
 (b) Placement Agent’s Warrants. On the Closing Date, the Company
will issue to the Placement Agent warrants (the “Placement Agent Warrants”), exercisable to purchase Shares 
  

 8 

 at a price equal to 120% of the per Share price of the Common Stock. The Placement Agent Warrants shall be exercisable
for a period of l five years after the Closing Date. The Placement Agent will receive such number of Placement Agent Warrants as will allow the Placement Agent to acquire a number of Shares equal to six percent (6%) of the total number of Shares
sold in the Offering. All the representations, covenants, warranties, undertakings, remedies, liquidated damages, indemnification, and other rights including but not limited to registration rights made or granted to or for the benefit of the
Subscribers are hereby also made and granted to the Placement Agent in respect of the Placement Agent’s Warrants and the Shares issuable upon exercise thereof. 
  
 9. Covenants of the Company. The Company covenants and agrees with the Subscribers as follows: 
  
 (a) Stop Orders. The Company will advise the Subscribers, promptly
after it receives notice of issuance by the Commission, any state securities commission or any other regulatory authority of any stop order or of any order preventing or suspending any offering of any securities of the Company, or of the suspension
of the qualification of the Common Stock of the Company for offering or sale in any jurisdiction, or the initiation of any proceeding for any such purpose. 
  
 (b) Listing. The Company shall promptly secure the listing of the shares of Common Stock and the Warrant Shares on the Principal Market or any
other automated quotation system or exchange upon which they are or become eligible for listing (subject to official notice of issuance) and shall maintain such listing so long as any Warrants are outstanding. The Company will maintain the listing
of its Common Stock on the Principal Market, and will comply in all material respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Principal Market, as applicable. The Company will provide the
Subscribers copies of all notices it receives notifying the Company of the threatened and actual delisting of the Common Stock from any Principal Market. 
  
 (c) Market Regulations. The Company shall notify the Commission, the Principal Market and applicable state authorities, in accordance with their
requirements, of the transactions contemplated by this Agreement, and shall take all other necessary action and proceedings as may be required and permitted by applicable law, rule and regulation, for the legal and valid issuance of the Securities
to the Subscribers and promptly provide copies thereof to Subscriber. 
  
 (d) Reporting Requirements. From the date of this Agreement and until the sooner of (i) two (2) years after the Closing Date, or (ii) until all the Shares and Warrant Shares have been resold or transferred by all the Subscribers
pursuant to the Registration Statement or pursuant to Rule 144, without regard to volume limitation, the Company will (v) cause its Common Stock to continue to be registered under Section 12(b) or 12(g) of the 1934 Act, (x) comply in all respects
with its reporting and filing obligations under the 1934 Act, (y) comply with all reporting requirements that are applicable to an issuer with a class of shares registered pursuant to Section 12(b) or 12(g) of the 1934 Act, as applicable, and (z)
comply with all requirements related to any registration statement filed pursuant to this Agreement. The Company will use its best efforts not to take any action or file any document (whether or not permitted by the 1933 Act or the 1934 Act or the
rules thereunder) to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under said acts until two (2) years after the Closing Date. Until the earlier of the resale of the Common Stock and the
Warrant Shares by each Subscriber or at least two (2) years after the Warrants have been exercised, the Company will use its best efforts to continue the listing or quotation of the Common Stock on the Principal Market or other market with the
reasonable consent of Subscribers holding a majority of the Shares and Warrant Shares, and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Principal Market. The Company
agrees to file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof to each Subscriber promptly after such filing. 
  

 9 

 (e) Use of Proceeds. The Company undertakes to use the proceeds of the Subscribers’ funds
for the purposes set forth on Schedule 9(e) hereto. A deviation from the use of proceeds set forth on Schedule 9(e) of more than 10% per item or more than 20% in the aggregate shall be deemed a material breach of the
Company’s obligations hereunder. Except as set forth on Schedule 9(e), the Purchase Price may not and will not be used for accrued and unpaid officer and director salaries, payment of financing related debt, redemption of
outstanding redeemable notes or equity instruments of the Company nor non-trade obligations outstanding on the Closing Date. 
  
 (f) Reservation. The Company undertakes to reserve, pro rata on behalf of each Subscriber and holder of a Warrant, from its authorized but
unissued common stock, a number of common shares equal to the amount of Warrant Shares issuable upon exercise of the Warrants. Failure to have sufficient shares reserved pursuant to this Section 9(f) for three (3) consecutive business days or ten
(10) days in the aggregate shall be a material default of the Company’s obligations under this Agreement. 
  
 (g) Taxes. From the date of this Agreement and until the sooner of (i) two (2) years after the Closing Date, or (ii) until all the Shares and
Warrant Shares have been resold or transferred by all the Subscribers pursuant to the Registration Statement or pursuant to Rule 144, without regard to volume limitations, the Company will promptly pay and discharge, or cause to be paid and
discharged, when due and payable, all lawful taxes, assessments and governmental charges or levies imposed upon the income, profits, property or business of the Company; provided, however, that any such tax, assessment, charge or levy need not be
paid if the validity thereof shall currently be contested in good faith by appropriate proceedings and if the Company shall have set aside on its books adequate reserves with respect thereto, and provided, further, that the Company will pay all such
taxes, assessments, charges or levies forthwith upon the commencement of proceedings to foreclose any lien which may have attached as security therefore. 
  
 (h) Insurance. From the date of this Agreement and until the sooner of (i) two (2) years after the Closing Date, or (ii) until all the Shares and
Warrant Shares have been resold or transferred by all the Subscribers pursuant to the Registration Statement or pursuant to Rule 144, without regard to volume limitations, the Company will keep its assets which are of an insurable character insured
by financially sound and reputable insurers against loss or damage by fire, explosion and other risks customarily insured against by companies in the Company’s line of business, in amounts sufficient to prevent the Company from becoming a
co-insurer and not in any event less than one hundred percent (100%) of the insurable value of the property insured; and the Company will maintain, with financially sound and reputable insurers, insurance against other hazards and risks and
liability to persons and property to the extent and in the manner customary for companies in similar businesses similarly situated and to the extent available on commercially reasonable terms. 
  
 (i) Books and Records. From the date of this Agreement and until the
sooner of (i) two (2) years after the Closing Date, or (ii) until all the Shares and Warrant Shares have been resold or transferred by all the Subscribers pursuant to the Registration Statement or pursuant to Rule 144, without regard to volume
limitations, the Company will keep true records and books of account in which full, true and correct entries will be made of all dealings or transactions in relation to its business and affairs in accordance with generally accepted accounting
principles applied on a consistent basis. 
  
 (j) Governmental
Authorities. From the date of this Agreement and until the sooner of (i) two (2) years after the Closing Date, or (ii) until all the Shares and Warrant Shares have 
  

 10 

 been resold or transferred by all the Subscribers pursuant to the Registration Statement or pursuant to Rule 144, without
regard to volume limitations, the Company shall duly observe and conform in all material respects to all valid requirements of governmental authorities relating to the conduct of its business or to its properties or assets. 
  
 (k) Intellectual Property. From the date of this Agreement and until
the sooner of (i) two (2) years after the Closing Date, or (ii) until all the Shares and Warrant Shares have been resold or transferred by all the Subscribers pursuant to the Registration Statement or pursuant to Rule 144, without regard to volume
limitations, the Company shall maintain in full force and effect its corporate existence, rights and franchises and all licenses and other rights to use intellectual property owned or possessed by it and reasonably deemed to be necessary to the
conduct of its business. 
  
 (l) Properties. From the date
of this Agreement and until the sooner of (i) two (2) years after the Closing Date, or (ii) until all the Shares and Warrant Shares have been resold or transferred by all the Subscribers pursuant to the Registration Statement or pursuant to Rule
144, without regard to volume limitation, the Company will keep its properties in good repair, working order and condition, reasonable wear and tear excepted, and from time to time make all necessary and proper repairs, renewals, replacements,
additions and improvements thereto; and the Company will at all times comply with each provision of all leases to which it is a party or under which it occupies property if the breach of such provision could reasonably be expected to have a material
adverse effect. 
  
 (m) Confidentiality/Public
Announcement. From the date of this Agreement and until the sooner of (i) two (2) years after the Closing Date, or (ii) until all the Shares and Warrant Shares have been resold or transferred by all the Subscribers pursuant to the Registration
Statement or pursuant to Rule 144, without regard to volume limitations, the Company agrees that it will not disclose publicly or privately the identity of the Subscribers unless expressly agreed to in writing by a Subscriber or only to the extent
required by law and then only upon ten days prior notice to Subscriber. The Company may identify the Subscribers in any registration statement filed pursuant to Section 11 of this Agreement. Notwithstanding the foregoing, the Company undertakes to
file a Form 8-K describing the Offering not later than the Closing Date. In the Form 8-K, the Company will specifically disclose the amount of common stock outstanding immediately after the Closing. In addition, it is acknowledged by the parties
hereto that the Company shall file copies of this Agreement, the Warrants and the Placement Agent Warrant as material contracts in its filings with the Securities and Exchange Commission. 
  
 (n) Further Registration Statements. Except for a registration statement filed on behalf of the Subscribers pursuant
to Section 11 of this Agreement or as otherwise set forth on Schedule 9(n), the Company will not file any registration statements, including but not limited to Form S-8, with the Commission or with state regulatory authorities without
the consent of the Subscribers holding 75% of the Shares sold hereunder including any Warrant Shares, if any (the “Applicable Percentage”) until 90 (90) days after the effective date of the Registration Statement filed on behalf of the
Subscribers during which such Registration Statement shall be current and available for use in connection with the public resale of the Shares and Warrant Shares (“Exclusion Period”). 
  
 (o) Blackout. The Company undertakes and covenants that without the
consent of the Applicable Percentage of the Subscribers which consent shall not be unreasonably withheld, until the first to occur of (i) the end of the Exclusion Period, or (ii) until all the Shares and Warrant Shares have been resold pursuant to
such registration statement, the Company will not enter into any acquisition, merger, exchange or sale or other transaction that could have the effect of delaying the effectiveness of any pending registration statement or causing an already
effective registration statement to no longer be effective or current. 
  

 11 

 10. Covenants of the Company and Subscribers Regarding Indemnification. 
  
 (a) The Company agrees to indemnify, hold harmless, reimburse and defend
the Subscribers, the Subscribers’ officers, directors, agents, affiliates, control persons, and principal shareholders, against any claim, cost, expense, liability, obligation, loss or damage (including reasonable legal fees) of any nature,
incurred by or imposed upon the Subscriber or any such person which results, arises out of or is based upon (i) any material misrepresentation by Company or breach of any warranty by Company in this Agreement or in any Exhibits or Schedules attached
hereto, or other agreement delivered pursuant hereto; or (ii) after any applicable notice and/or cure periods, any breach or default in performance by the Company of any covenant or undertaking to be performed by the Company hereunder, or any other
agreement entered into by the Company and any Subscriber or the Subscribers relating hereto. 
  
 (b) Each Subscriber agrees to indemnify, hold harmless, reimburse and defend the Company and each of the Company’s officers, directors, agents, affiliates, control persons against any claim, cost, expense,
liability, obligation, loss or damage (including reasonable legal fees) of any nature, incurred by or imposed upon the Company or any such person which results, arises out of or is based upon (i) any material misrepresentation by such Subscriber in
this Agreement or in any Exhibits or Schedules attached hereto, or other agreement delivered pursuant hereto; or (ii) after any applicable notice and/or cure periods, any breach or default in performance by such Subscriber of any covenant or
undertaking to be performed by such Subscriber hereunder, or any other agreement entered into by the Company and Subscribes relating hereto. 
  
 (c) In no event shall the liability of any Subscriber or permitted successor hereunder or under any other agreement delivered in connection herewith be
greater in amount than the dollar amount of the net proceeds actually received by such Subscriber upon the sale of Shares or Shares issuable upon exercise of Warrants (“Registrable Securities”). 
  
 (d) The procedures set forth in Section 11.6 shall apply to the
indemnifications set forth in Sections 10(a) and 10(b) above. 
  
 11.1. Registration Rights. The Company hereby grants the following registration rights to holders of the Securities. 
  
 (i) Not later than 30 days after the Closing Date (the “Filing Date”), the Company shall prepare and file with the Commission a registration
statement under the 1933 Act registering the Shares and Warrant Shares including Warrant Shares issuable upon exercise of the Placement Agent’s Warrants (collectively “Registrable Securities”) for unrestricted public resale by the
holder thereof. The Company will cause such registration statement to be declared effective within 90 days after the Closing Date (the “Effective Date”), a Form SB-3 registration statement (the “Registration Statement”) (or such
other form that it is eligible to use) in order to register the Registrable Securities for resale and distribution under the 1933 Act. The Company will register not less than a number of shares of common stock that is equal to all of the Shares and
Warrant Shares issuable pursuant to this Agreement. The Registrable Securities shall be reserved and set aside exclusively for the benefit of each Subscriber and Warrant holder, pro rata, and not issued, employed or reserved for anyone
other than each such Subscriber and Warrant holder. The Registration Statement will immediately be amended or additional registration statements will be immediately filed by the Company as necessary to register additional shares of Common Stock to
allow the public resale of all Common Stock included in and issuable by virtue of the Registrable Securities. Without the written consent of the Applicable Percentage of the Subscribers, no securities of the Company other than the Registrable
Securities will be included in the Registration Statement. 
  

 12 

 11.2. Registration Procedures. If and whenever the Company is required by the provisions of
Section 11.1(i) to effect the registration of any Registrable Securities under the 1933 Act, the Company will, as expeditiously as possible: 
  
 (a) subject to the timelines provided in this Agreement, prepare and file with the Commission a registration statement required by Section 11, with
respect to such securities and use its best efforts to cause such registration statement to become and remain effective for the period of the distribution contemplated thereby (determined as herein provided), and promptly provide to the holders of
Registrable Securities copies of all filings and Commission letters of comment; 
  
 (b) prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective
until such registration statement has been effective for a period of two (2) years, and comply with the provisions of the 1933 Act with respect to the disposition of all of the Registrable Securities covered by such registration statement in
accordance with the Subscribers’ intended method of disposition set forth in such registration statement for such period; 
  
 (c) furnish to the Subscribers, at the Company’s expense, such number of copies of the registration statement and the prospectus included therein
(including each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale or their disposition of the securities covered by such registration statement; 
  
 (d) use its best efforts to register or qualify the Sunscribers’
Registrable Securities covered by such registration statement under the securities or “blue sky” laws of such jurisdictions as the Subscribers shall request in writing, provided, however, that the Company shall not for any such purpose be
required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so qualified or to consent to general service of process in any such jurisdiction; 
  
 (e) if applicable, list the Registrable Securities covered by such
registration statement with any securities exchange on which the Common Stock of the Company is then listed; 
  
 (f) immediately notify the Subscribers when a prospectus relating thereto is required to be delivered under the 1933 Act, of the happening of any event
of which the Company has knowledge as a result of which the prospectus contained in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or
necessary to make the statements therein not misleading in light of the circumstances then existing; and 
  
 (g) provided same would not be in violation of the provision of Regulation FD under the 1934 Act, make available for inspection by the Subscribers, and
any attorney, accountant or other agent retained by the Subscriber or underwriter, all publicly available, non-confidential financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s
officers, directors and employees to supply all publicly available, non-confidential information reasonably requested by the seller, attorney, accountant or agent in connection with such registration statement. 
  
 11.3. Provision of Documents. In connection with each registration
described in this Section 11, each Subscriber will furnish to the Company in writing such information and representation letters with respect to itself and the proposed distribution by it as reasonably shall be necessary in order to assure
compliance with federal and applicable state securities laws. 
  
 11.4. Non-Registration Events. The Company and the Subscribers agree that the Subscribers will suffer damages if the Registration Statement is not filed by the Filing Date and not 
  

 13 

 declared effective by the Commission by the Effective Date, and it would not be feasible to ascertain the extent of such
damages with precision. Accordingly, if (i) the Registration Statement is not filed on or before the Filing Date or is not declared effective on or before the sooner of the Effective Date, or within three (3) business days of receipt by the Company
of a written or oral communication from the Commission that the Registration Statement will not be reviewed, or (ii) any registration statement described in Sections 11.1(i) is filed and declared effective but shall thereafter cease to be effective
(without being succeeded within ten (10) business days by an effective replacement or amended registration statement) for a period of time which shall exceed 30 days in the aggregate per year (defined as a period of 365 days commencing on the date
the Registration Statement is declared effective) or more than 20 consecutive days (each such event referred to in clauses (i) and (ii) of this Section 11.4 is referred to herein as a “Non-Registration Event”), then the Company shall
deliver to the holder of Registrable Securities, as liquidated damages, an amount equal to one percent (1%) for each thirty days or part thereof of the Purchase Price of the Shares and actually paid “Purchase Price” (as defined in the
Warrants) of Warrant Shares issued or issuable upon actual exercise of the Warrants, for the Registrable Securities owned of record by such holder as of and during the pendency of such Non-Registration Event which are subject to such
Non-Registration Event. The Company must pay the liquidated damages in cash within ten (10) days after the end of each thirty (30) day period or shorter part thereof for which liquidated Damages are payable. In the event a Registration Statement is
filed by the Filing Date but is withdrawn prior to being declared effective by the Commission, then such Registration Statement will be deemed to have not been filed. 
  
 11.5. Expenses. All expenses incurred by the Company in complying with Section 11, including, without limitation, all
registration and filing fees, printing expenses, fees and disbursements of counsel and independent public accountants for the Company, fees and expenses (including reasonable counsel fees) incurred in connection with complying with state securities
or “blue sky” laws, fees of the National Association of Securities Dealers, Inc., transfer taxes, fees of transfer agents and registrars, costs of insurance and fee of one counsel for all Subscribers (in an amount not to exceed $5,000) are
called “Registration Expenses.” All underwriting discounts and selling commissions applicable to the sale of Registrable Securities, including any fees and disbursements of any additional counsel to the Subscriber, are called “Selling
Expenses.” The Company will pay all Registration Expenses in connection with the registration statement under Section 11. Selling Expenses in connection with each registration statement under Section 11 shall be borne by the Subscriber and may
be apportioned among the Subscribers in proportion to the number of shares sold by the Subscriber relative to the number of shares sold under such registration statement or as all Subscribers thereunder may agree. 
  
 11.6. Indemnification and Contribution. 
  
 (a) In the event of a registration of any Registrable Securities under the
1933 Act pursuant to Section 11, the Company will, to the extent permitted by law, indemnify and hold harmless the Subscriber, each officer of the Subscriber, each director of the Subscriber, each underwriter of such Registrable Securities
thereunder and each other person, if any, who controls such Subscriber or underwriter within the meaning of the 1933 Act, against any losses, claims, damages or liabilities, joint or several, to which the Subscriber, or such underwriter or
controlling person may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any
material fact contained in any registration statement under which such Registrable Securities was registered under the 1933 Act pursuant to Section 11, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement
thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances when made, and will,
subject to the provisions of Section 11.6(c), 
  

 14 

 reimburse the Subscriber, each such underwriter and each such controlling person for any reasonable legal or other
expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company shall not be liable to the Subscriber to the extent that any such damages arise
out of or are based upon an untrue statement or omission made in any preliminary prospectus if (i) the Subscriber failed to send or deliver a copy of the final prospectus delivered by the Company to the Subscriber with or prior to the delivery of
written confirmation of the sale by the Subscriber to the person asserting the claim from which such damages arise, (ii) the final prospectus would have corrected such untrue statement or alleged untrue statement or such omission or alleged
omission, or (iii) to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by any
such Subscriber, or any such controlling person in writing specifically for use in such registration statement or prospectus. 
  
 (b) In the event of a registration of any of the Registrable Securities under the 1933 Act pursuant to Section 11, each Subscriber severally but not
jointly will, to the extent permitted by law, indemnify and hold harmless the Company, and each person, if any, who controls the Company within the meaning of the 1933 Act, each officer of the Company who signs the registration statement, each
director of the Company, each underwriter and each person who controls any underwriter within the meaning of the 1933 Act, against all losses, claims, damages or liabilities, joint or several, to which the Company or such officer, director,
underwriter or controlling person may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue
statement of any material fact contained in the registration statement under which such Registrable Securities were registered under the 1933 Act pursuant to Section 11, any preliminary prospectus or final prospectus contained therein, or any
amendment or supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the
Company and each such officer, director, underwriter and controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action, provided,
however, that the Subscriber will be liable hereunder in any such case if and only to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged
omission made in reliance upon and in conformity with information pertaining to such Subscriber, as such, furnished in writing to the Company by such Subscriber specifically for use in such registration statement or prospectus, and provided,
further, however, that the liability of the Subscriber hereunder shall be limited to the net proceeds actually received by the Subscriber from the sale of Registrable Securities covered by such registration statement. 
  
 (c) Promptly after receipt by an indemnified party hereunder of notice of
the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party in writing thereof, but the omission so to notify the indemnifying
party shall not relieve it from any liability which it may have to such indemnified party other than under this Section 11.6(c) and shall only relieve it from any liability which it may have to such indemnified party under this Section 11.6(c),
except and only if and to the extent the indemnifying party is prejudiced by such omission. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the
indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel satisfactory to such indemnified party, and, after notice from the indemnifying party to such
indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not be liable to such indemnified party under this Section 11.6(c) for any legal expenses subsequently incurred by such indemnified party
in connection with the defense thereof 
  

 15 

 other than reasonable costs of investigation and of liaison with counsel so selected, provided, however, that, if the
defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be reasonable defenses available to it which are different from or additional to
those available to the indemnifying party or if the interests of the indemnified party reasonably may be deemed to conflict with the interests of the indemnifying party, the indemnified parties, as a group, shall have the right to select one
separate counsel and to assume such legal defenses and otherwise to participate in the defense of such action, with the reasonable expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by the
indemnifying party as incurred. 
  
 (d) In order to provide for
just and equitable contribution in the event of joint liability under the 1933 Act in any case in which either (i) a Subscriber, or any controlling person of a Subscriber, makes a claim for indemnification pursuant to this Section 11.6 but it is
judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case
notwithstanding the fact that this Section 11.6 provides for indemnification in such case, or (ii) contribution under the 1933 Act may be required on the part of the Subscriber or controlling person of the Subscriber in circumstances for which
indemnification is not provided under this Section 11.6; then, and in each such case, the Company and the Subscriber will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from
others) in such proportion so that the Seller is responsible only for the portion represented by the percentage that the public offering price of its securities offered by the registration statement bears to the public offering price of all
securities offered by such registration statement, provided, however, that, in any such case, (y) the Subscriber will not be required to contribute any amount in excess of the public offering price of all such securities offered by it pursuant to
such registration statement; and (z) no person or entity guilty of fraudulent misrepresentation (within the meaning of Section 10(f) of the 1933 Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent
misrepresentation. 
  
 11.7. Delivery of Unlegended Shares.

  
 (a) Within three (3) business days (such third business day,
the “Unlegended Shares Delivery Date”) after the business day on which the Company has received (i) a notice that Registrable Securities have been sold either pursuant to the Registration Statement or Rule 144 under the 1933 Act, (ii) a
representation that the prospectus delivery requirements, or the requirements of Rule 144, as applicable, have been satisfied, and (iii) the original share certificates representing the shares of Common Stock that have been sold, and (iv) in the
case of sales under Rule 144 customary representation letters of the Subscriber and Subscriber’s broker regarding compliance with the requirements of Rule 144, the Company at its expense, (y) shall deliver, and shall cause legal counsel
selected by the Company to deliver, to its transfer agent (with copies to the Subscribers requesting such opinion) an appropriate instruction and opinion of such counsel, directing the delivery of shares of Common Stock without any legends including
the legends set forth in Sections 4(e) and 4(f) above, issuable pursuant to any effective and current registration statement described in Section 11 of this Agreement or pursuant to Rule 144 under the 1933 Act (the “Unlegended Shares”);
and (z) cause the transmission of the certificates representing the Unlegended Shares together with a legended certificate representing the balance of the unsold shares of Common Stock, if any, to the Subscriber at the address specified in the
notice of sale, via express courier, by electronic transfer or otherwise on or before the Unlegended Shares Delivery Date. Transfer fees shall be the responsibility of the Subscriber. 
  
 (b) In lieu of delivering physical certificates representing the Unlegended Shares, if the Company’s transfer agent is
participating in the Depository Trust Company (“DTC”) Fast 
  

 16 

 Automated Securities Transfer program, upon request of a Subscriber, so long as the certificates therefor do not bear a
legend and the Subscriber is not obligated to return such certificate for the placement of a legend thereon, the Company shall cause its transfer agent to electronically transmit the Unlegended Shares by crediting the account of Subscriber’s
prime Broker with DTC through its Deposit Withdrawal Agent Commission system. Such delivery must be made on or before the Unlegended Shares Delivery Date. 
  
 (c) The Company understands that a delay in the delivery of the Unlegended Shares pursuant to Section 11 hereof beyond the Unlegended Shares Delivery
Date could result in economic loss to a Subscriber. As compensation to a Subscriber for such loss, the Company agrees to pay late payment fees (as liquidated damages and not as a penalty) to the Subscriber for late delivery of Unlegended Shares in
the amount of $100 per business day after the Delivery Date for each $10,000 of purchase price of the Unlegended Shares subject to the delivery default. If during any 360 day period, the Company fails to deliver Unlegended Shares as required by this
Section 11.7 for an aggregate of thirty (30) days, then each Subscriber or assignee holding Securities subject to such default may, at its option, require the Company to purchase all or any portion of the Shares and Warrant Shares subject to such
default at a price per share equal to 130% of the Purchase Price of such Common Stock and Warrant Shares. The Company shall pay any payments incurred under this Section in immediately available funds upon demand. 
  
 (d) In addition to any other rights available to a Subscriber, if the
Company fails to deliver to a Subscriber Unlegended Shares as required pursuant to this Agreement, within ten (10) calendar days after the Unlegended Shares Delivery Date and the Subscriber purchases (in an open market transaction or otherwise)
shares of common stock to deliver in satisfaction of a sale by such Subscriber of the shares of Common Stock which the Subscriber anticipated receiving from the Company (a “Buy-In”), then the Company shall pay in cash to the Subscriber (in
addition to any remedies available to or elected by the Subscriber) the amount by which (A) the Subscriber’s total purchase price (including brokerage commissions, if any) for the shares of common stock so purchased exceeds (B) the aggregate
purchase price of the shares of Common Stock delivered to the Company for reissuance as Unlegended Shares, together with interest thereon at a rate of 15% per annum, accruing until such amount and any accrued interest thereon is paid in full (which
amount shall be paid as liquidated damages and not as a penalty). For example, if a Subscriber purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to $10,000 of purchase price of shares of Common
Stock delivered to the Company for reissuance as Unlegended Shares, the Company shall be required to pay the Subscriber $1,000, plus interest. The Subscriber shall provide the Company written notice indicating the amounts payable to the Subscriber
in respect of the Buy-In. 
  
 (e) In the event a Subscriber shall
request delivery of Unlegended Shares as described in Section 11.7(a), the Company may not refuse to deliver Unlegended Shares based on any claim that such Subscriber or any one associated or affiliated with such Subscriber has been engaged in any
violation of law, or for any other reason, unless, an injunction or temporary restraining order from a court, on notice, restraining and or enjoining delivery of such Unlegended Shares or exercise of all or part of said Warrant shall have been
sought and obtained and the Company has posted a surety bond for the benefit of such Subscriber in the amount of 130% of the amount of the aggregate purchase price of the Common Stock and Warrant Shares which are subject to the injunction or
temporary restraining order, which bond shall remain in effect until the completion of arbitration/litigation of the dispute and the proceeds of which shall be payable to such Subscriber to the extent Subscriber obtains judgment in Subscriber’s
favor. 
  
 12. (a) Right of First Refusal. During the
Exclusion Period, the Subscribers shall be given not less than seven (7) business days prior written notice of any proposed sale by the Company of 
  

 17 

 its common stock or other securities or debt obligations, except in connection with (i) employee stock options or
compensation plans, (ii) as full or partial consideration in connection with any merger, consolidation or purchase of substantially all of the securities or assets of any corporation or other entity, or (iii) as has been described in the Reports or
Other Written Information filed or delivered prior to the Closing Date (collectively “Excepted Issuances”). The Subscribers who exercise their rights pursuant to this Section 12(a) shall have the right during the seven (7) business days
following receipt of the notice to purchase all of such offered common stock, debt or other securities in accordance with the terms and conditions set forth in the notice of sale in the same proportion to each other as their purchase of Shares in
the Offering. In the event such terms and conditions are modified during the notice period, the Subscribers shall be given prompt notice of such modification and shall have the right during the original notice period or for a period of seven (7)
business days following the notice of modification, whichever is longer, to exercise such right. 
  
 (b) Offering Restrictions. Until the Registration Statement is filed, except in connection with the Excepted Issuances or the Offering, the
Company will not enter into any agreement to, nor issue any equity, convertible debt or other securities convertible into common stock without the prior written consent of Subscribers holding not less than a majority of the Shares and, if issued,
Warrant Shares, which consent may be withheld for any reason. 
  
 (c) Maximum Exercise of Rights. In the event the exercise of the rights described in Sections 12(a) would result in the issuance of an amount of common stock of the Company that would exceed the maximum amount that may be issued to a
Subscriber calculated in the manner described in Section 10 of the Warrant, then the issuance of such additional shares of common stock of the Company to such Subscriber will be deferred in whole or in part until such time as such Subscriber is able
to beneficially own such common stock without exceeding the maximum amount set forth calculated in the manner described in Section 10 of the Warrant. The determination of when such Common Stock may be issued shall be made by each Subscriber as to
only such Subscriber. 
  
 13. Miscellaneous. 
  
 (a) Notices. All notices, demands, requests, consents, approvals,
and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid,
(iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written
notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the
address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business
hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The
addresses for such communications shall be: (i) if to the Company, to: Commonwealth Biotechnologies, Inc., 601 Biotech Drive, Richmond, Virginia 23235, Attn: Dr. Robert B. Harris, President and Chief Executive Officer, telecopier: (804)915-3830),
with a copy by telecopier only to: Kaufman & Canoles, Three James Center, 1051 East Cary Street, 12th Floor,
Richmond, VA 23219, Attn: Bradley A. Haneberg, Esq., telecopier: (804) 771-5777, and (ii) if to the Subscribers, to: the one or more addresses and telecopier numbers indicated on the signature pages hereto, with an additional copy by telecopier only
to: Sichenzia Ross Friedman Ference LLP, 1065 Avenue of the Americas, New York, NY 10018, Attn: Marc Ross, Esq., telecopier: (212) 930-9725. 
  

 18 

 (b) Closing. The consummation of the transactions contemplated herein shall take place at the
offices of Sichenzia Ross Friedman Ference LLP, 1065 Avenue of the Americas, New York, NY 10018, upon the satisfaction of all conditions to Closing set forth in this Agreement, but not later than May 28, 2004 (“Closing Date”). 

 
 (c) Entire Agreement; Assignment. This Agreement and other
documents delivered in connection herewith represent the entire agreement between the parties hereto with respect to the subject matter hereof and may be amended only by a writing executed by both parties. Neither the Company nor the Subscribers
have relied on any representations not contained or referred to in this Agreement and the documents delivered herewith. No right or obligation of either party shall be assigned by that party without prior notice to and the written consent of the
other party. 
  
 (d) Counterparts/Execution. This
Agreement may be executed in any number of counterparts and by the different signatories hereto on separate counterparts, each of which, when so executed, shall be deemed an original, but all such counterparts shall constitute but one and the same
instrument. This Agreement may be executed by facsimile signature and delivered by facsimile transmission. 
  
 (e) Law Governing this Agreement. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the
state of New York. The parties and the individuals executing this Agreement and other agreements referred to herein or delivered in connection herewith on behalf of the Company agree to submit to the jurisdiction of such courts and waive trial by
jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or
unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision
which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. 
  
 (f) Specific Enforcement, Consent to Jurisdiction. The Company and Subscriber acknowledge and agree that irreparable damage would occur in the
event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent or cure
breaches of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, this being in addition to any other remedy to which any of them may be entitled by law or equity. Subject to Section 13(e) hereof, each of the
Company, Subscriber and any signator hereto in his personal capacity hereby waives, and agrees not to assert in any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction in New York of such court, that the
suit, action or proceeding is brought in an inconvenient forum or that the venue of the suit, action or proceeding is improper. Nothing in this Section shall affect or limit any right to serve process in any other manner permitted by law.

  
 (g) Independent Nature of Subscribers’ Obligations
and Rights. The obligations of each Subscriber hereunder are several and not joint with the obligations of any other Subscriber hereunder, and no such Subscriber shall be responsible in any way for the performance of the obligations of any other
hereunder. 
  

 19 

 (h) Equitable Adjustment. The Securities and the purchase prices of Securities shall be equitably
adjusted to offset the effect of stock splits, stock dividends, and distributions of property or equity interests of the Company to its shareholders. 
  
 [THIS SPACE INTENTIONALLY LEFT BLANK] 
  

 20 

 SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT 
  
 Please acknowledge your acceptance of the foregoing Subscription Agreement by
signing and returning a copy to the undersigned whereupon it shall become a binding agreement between us. 
  

			
	 COMMONWEALTH BIOTECHNOLOGIES, INC.

		
	 By:
	 	 /s/ Robert B. Harris, PhD

	 Name:
	 	 Robert B. Harris, PhD

	 Title:
	 	 President and Chief Executive Officer

		
	 	 	 Dated: May 27, 2004

  

			
	 AGREED AND ACCEPTED:

	
	 SUBSCRIBER: Omicron Master Trust

	
	 Print Name: Bruce Bernstein

	
	 Address: 810 Seventh Ave. 39th Fl
 New York, NY 10019

	
	 Fax: 212 803-6269

		
	 By:
	 	 /s/    Bruce Bernstein

	 	 	             (Signature)

	 Title:
	 	 Managing Partner

  

			
	 Purchase Price: $250,000

	 Shares: 40,000

	 Warrants: 12,000

			
	 AGREED AND ACCEPTED:

	
	 SUBSCRIBER:

	
	 Print Name: Iroguois Capital LP

	
	 Address:      691 Lexington Ave., 26th Fl.

	
	                      New
York, NY 10022

	
	 Fax:                                    
                                        
                  

		
	 By:
	 	 /s/    Josh Silverman

	 	 	             (Signature)

	 Title:
	 	            Partner

  

	
	Purchase Price: $ 750,000
	Shares: 120,000
	Warrants: 30,000

  

			
	 AGREED AND ACCEPTED:

	
	 SUBSCRIBER:

	
	Print Name: Deutsche Suisse Asset
Management,
                     Ltd. for DSAM Fund LP
	
	 Address: c/o Goldman Sachs (Cayman) Trust

	
	North Church Street, P.O. Box 689, Crand Cayman,
Cayman Islands, BWI
	
	 Fax: (305) 675-8035

		
	 By:
	 	 /s/    Angela Morrone

	 	 	             (Signature)

	 Title:
	 	            President

  

	
	Purchase Price: $ 1,500,000
	Shares: 240,000
	Warrants: 60,000

 LIST OF EXHIBITS AND SCHEDULES 
  

			
	 Exhibit A
	  	 Form of Warrant

		
	 Exhibit B
	  	 Escrow Agreement

		
	 Exhibit C
	  	 Form of Legal Opinion

		
	 Schedule 5(d)
	  	 Additional Issuances

		
	 Schedule 5(q)
	  	 Undisclosed Liabilities

		
	 Schedule 5(s)
	  	 Capitalization

		
	 Schedule 9(e)
	  	 Use of ProceedsAmendment 1 to the Large-Scale Product Supply Agreement

 Exhibit 10.1 
  
 CONFIDENTIAL 
 TREATMENT REQUEST 
  
  

 CERTAIN PORTIONS INDICATED BY *** HAVE BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED NON-PUBLIC PORTIONS HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

  
  
 Amendment 1 
  
 To the Large-Scale Product Supply
Agreement dated December 18, 2002 (“Agreement”), between Lonza Biologics PLC an English Corporation (“LB”), with offices at 228 Bath Road, Slough, Berkshire SL14DY, England, and Alexion Pharmaceuticals Inc., a Delaware
corporation (“Alexion”), with offices at 352 Knotter Drive, Cheshire, Connecticut 06410 
  
 THIS AMENDMENT (Amendment 1) is made this 9th day of April 2004 (the “Amendment 1 Effective Date”) 
  
 BETWEEN: 
  
 Lonza Biologics Plc. 
 228 Bath Road 
 Slough, Berkshire, SL1 4DX 
 England                     (“LB”);

  
 and 
  
 Alexion Pharmaceuticals Inc. 
 352 Knotter Drive 
 Cheshire CT 06410
                (“Alexion”). 
  
  
 WITNESSETH: 
  
 WHEREAS, LB and Alexion wish to amend the Agreement under the terms and
conditions contained herein; 
  
 NOW, THEREFORE, in consideration
of the mutual terms, covenants and conditions contained in this Amendment 1, the Parties hereto agree as follows: 
  
 1.  Withdrawal Fee.  Alexion and LB acknowledge that Alexion has previously paid LB $10,000,000 in prepayments under the Agreement. The Parties
agree that Alexion will pay LB $8,500,000 as further consideration for execution and performance by LB of this Amendment, which amount shall be satisfied by a deduction from such $10,000,000 prepayment. The $1,500,000 remaining from such prepayment
shall be credited against the $5,000,000 payment to LB by Alexion under Section 13.15. 
  
 2.  Section 1.1.1 (“Advance”).  Section 1.1.1 shall be amended to read in its entirety as follows: 
  
 “Advance” means the non-refundable $5,000,000 paid by Alexion pursuant to Section 13.15. 
  
  

 Page 1 of 12 

 3.  Section 1.1.9 (“Batch Price”).  The phrase “, among other things:” in
the third line of Section 1.1.9 shall be deleted and replaced by the phrase “all costs of Raw Materials and, among other things:” 
  
 4.  Section 1.1.14 (“Consistency Batches”).  Section 1.1.14 shall be amended such that the words “Consistency Batches”
shall be replaced by “Validation Batches” and no other change. Further, all references to “Consistency Batches” found throughout the Agreement are hereby replaced by the phrase “Validation Batches.” 
  
 5.  Section 1.1.15 (“Consistency Suite Use
Period”).  Section 1.1.15 shall be deleted in its entirety and the words “This Section left intentionally blank” shall be inserted in its stead. 
  
 6.  Section 1.1.20 (“Fermenter Train”).  Section 1.1.20 shall be amended to read in its entirety as
follows: 
  
 “‘Fermenter Train’ means ***
**** reactors and a ***** ***** production reactor.” 
  
 7.  Section 1.1.21 (“First Suite Use Period”).  Section 1.1.21 shall be deleted in its entirety and the words “This Section left intentionally blank” shall be inserted in its stead. 

 
 8.  Section 1.1.23 (“Large-Scale Development Services
Agreement”).  Section 1.1.23 shall be deleted in its entirety and the words “This Section left intentionally blank” shall be inserted in its stead. 
  
 9.  Section 1.1.24 (“Large Scale Manufacturing Suite”).  Section 1.1.24 shall be deleted in its
entirety and the words “This Section left intentionally blank” shall be inserted in its stead. 
  
 10.  Section 1.1.31 (“Letter of Intent”).  Section 1.1.31 shall be deleted in its entirety and the words “This Section left intentionally blank” shall be inserted in its
stead. 
  
 11.  Section 1.1.33 (“Maximum
Order”).  Section 1.1.33 shall be deleted in its entirety and the words “This Section left intentionally blank” shall be inserted in its stead. 
  
 12.  Section 1.1.34 (“Minimum Order”).  Section 1.1.34 shall be amended to read in its entirety as
follows: 
  
 “‘Minimum Order’ shall mean ******
**** ******* on or prior to December 31, 2008. The *** *** Pre-Validation Batches and **** *** Validation Batches, referred to in Section 13.1 are excluded from the ****** **** ****** Minimum Order. The ****** ****
****** Minimum Order will be decreased by the number of batches of any other products the Parties agree for LB to manufacture at ***** ***** scale.” 
  
  

 Page 2 of 12 

 13.  Section 1.1.43 (“Raw Materials Fee”).  Section 1.1.43 shall be deleted in its
entirety and the words “This Section left intentionally blank” shall be inserted in its stead. 
  
 14.  Section 1.1.48 (“Suite Year”).  Section 1.1.48 shall be deleted in its entirety and the words “This Section left intentionally blank” shall be inserted in its stead.

  
 15.  Section 1.1.49 (“Suite Use Commencement
Date”).  Section 1.1.49 shall be deleted in its entirety and the words “This Section left intentionally blank” shall be inserted in its stead. 
  
 16.  Section 1.1.50 (“Suite Use Period”).  Section 1.1.50 shall be deleted in its entirety and the
words “This Section left intentionally blank” shall be inserted in its stead. 
  
 17.  Section 1.1.55 (“***** ***** Manufacturing Suite”).  A new Section 1.1.55 shall be inserted, as follows: 
  
 “1.1.55. ‘***** ***** Manufacturing Suite’ means the ****** scale cGMP manufacturing Suite of
LB at its *********** *** ******** manufacturing site, which shall include the Fermenter Train and associated harvest and purification equipment.” 
  

18.  Section 2.1 (“Term”).  Section 2.1 shall be amended to read in its entirety as follows: 
  
 “This Agreement shall take effect on the Effective Date and shall,
unless sooner terminated pursuant to Section 18 as amended, remain in effect until December 31, 2008. Notwithstanding the foregoing:” 
  
 19.  Section 2.1.1 (“Term”).  Section 2.1.1 shall be amended to read in its entirety as follows: 
  
 “Upon written notice by Alexion to LB on or before the *****
anniversary of the Amendment 1 Effective Date, the initial term of this Agreement shall be extended for a ********* period. Alexion shall be entitled to purchase a maximum of ** Batches per year, subject to the limitations of LB’s
schedule and freely available capacity during such four year extension. Within 30 days of LB’s receipt of Alexion’s written request to extend the term, LB will provide Alexion in writing all details regarding its schedule and freely
available capacity during such ********* extension, insofar as such details are reasonably relevant for Alexion to understand LB’s ability to manufacture Large-scale product during such ********* extension. Alexion will have 30
days following receipt of such details to provide LB a Forecast Order for such ********* extension in respect of Batches that can be accommodated within LB’s schedule and do not exceed LB’s available capacity. Such Forecast Order
and Binding Orders in respect 
  
  

 Page 3 of 12 

 thereof shall be deemed covered by this Agreement in accordance with the terms of this Agreement,
including Sections 5.1 and 5.2.” 
  
 20.  Section 2.1.2
(“Term”).  Section 2.1.2 shall be amended as follows: 
  

	 	a.	the phrase “Suite Use Commencement Date” found therein shall in each case be deleted and replaced by the phrase “Amendment 1 Effective Date;”

  

	 	b.	the phrase “Large-Scale-Manufacturing Suite” found therein shall in each case be deleted and replaced by the phrase “***** ***** Manufacturing Suite;” and

  

	 	c.	the following phrase will be added to the end of Section 2.1.2: “Alexion would be entitled to purchase a maximum of ** Batches per year during such **** ****
extension.” 

  
 21.  Section 4.1 (“cGMP
Manufacturing”).  Section 4.1 shall be amended to read in its entirety as follows: 
  
 “cGMP Manufacture: Subject to Section 6.3, LB will, in accordance with the terms of this Agreement, manufacture and Deliver to Alexion Batches of
Large-Scale Product at ***** ***** scale in accordance with cGMP using the ***** ***** Manufacturing Suite. Additional product-specific development documentation and validation work required to support regulatory applications and to
conduct clinical trials or market a product shall be conducted by LB as reasonably requested by Alexion and as further agreed to between Parties, following good faith negotiations.” 
  
 22. Section 4.2.1 (“LB Services”). Section 4.2.1 shall be amended to read in its entirety as follows: 
  
 “Recover ampoules of the cell bank for the Cell Line and expand
cultures to complete airlift fermentation at ***** ***** scale in the ***** ***** Manufacturing Suite, using the Large-Scale Process for the Large-Scale Product. Each Batch shall be produced as one lot from one ampoule of the cell
bank.” 
  
 23.  Section 4.2.2 (“LB
Services”).  Section 4.2.2 shall be amended to read in its entirety as follows: 
 “Clarify culture supernatant and purify using the
Large-Scale Process.” 
  
 24.  Section 4.2.6 (“Issue a
certificate of analysis”).  Section 4.2.6 shall be amended to read in its entirety as follows: 
  
 “Issue a certificate of analysis sixty four (64) days from the date of bulk fill of the Product or such later date as reasonably requested by
Alexion” 
  
  

 Page 4 of 12 

 25.  Section 5.1 (“Forecast Order”).  Section 5.1 shall be amended to read in its
entirety: 
  
 “Alexion shall notify LB in writing of the
projected Batches to be manufactured in each year of the initial term of the Agreement and such subsequent years as applicable, refer to the current Forecast Order, refer to Attachment 1. The Forecast Order shall be Alexion’s best estimate for
Batches to be manufactured in each year of the Agreement. The projected Commencement date for manufacture of such Batches in each calendar year shall be provided by LB and may be revised by LB to any other date within the same calendar year upon
written notice thereof to Alexion. LB may not revise the Commencement date for manufacture of any Batch under this Section 5.1 after Alexion submits a Binding Order in respect thereof under Section 5.2. For the avoidance of doubt, however, LB does
retain rights to revise Commencement dates in accordance with Section 5.2.” 
  
 26.  Section 5.2 (“Binding Order”).  Section 5.2 shall be amended to read in its entirety: 
  
 “Not later than ** months before the beginning of any calendar quarter, Alexion shall notify LB in writing of the actual number of Batches it
is ordering for commencement in that quarter, with indicated Commencement dates, which shall be deemed the date scheduled for the start of manufacture hereunder. Upon LB’s receipt of such order a “Binding Order” shall arise in respect
of the number of ordered Batches that is equal to or fewer than the number set forth for such quarter in the Forecast Order. LB shall notify Alexion within 30 days of receipt of such notice whether it can Commence additional Batches requested by
Alexion during such calendar quarter, in which case the number of additional Batches it can Commence will be added to the Binding Order. LB shall use commercially reasonable efforts to manufacture any additional Batches requested by Alexion. Under a
“Binding Order” LB shall be committed to manufacture such Batches and Alexion shall be committed to pay for such Batches, in accordance with the terms of this Agreement. LB may revise the Commencement date of any Batch subject to a Binding
Order, but not by more than 3 months without Alexion’s written consent. 
  
 27.  Section 6.2 (“Scheduling of Suite Use Periods”).  Section 6.2 shall be deleted in its entirety and the words “This Clause left intentionally blank” shall be inserted in its stead.

  
 28.  Section 6.5 (“Procedure to Cure Supply
Deficiencies”).  Section 6.5 shall be amended to read in its entirety as follows: 
  
 “If there is a Supply Deficiency, LB shall increase the then current Large-Scale Product campaign (or if no longer current, then the next succeeding

  
  

 Page 5 of 12 

 Large-Scale Product campaign if not remedied beforehand) by ***** ***** and take one or more of
the following steps to remedy any remaining Supply Deficiency, as determined by the Steering Committee:” 
  
 29.  Sections 6.5.1 and 6.5.2 (“Procedure to Cure Supply Deficiencies”).  Sections 6.5.1 and 6.5.2 shall be amended as follows: 
  
 The phrase “Large Scale Manufacturing Suite” found therein shall
in each case be deleted and replaced by the phrase “***** ***** Manufacturing Suite.” 
  
 30.  Section 6.6 (“Pro Rata Allocation”).  Section 6.6 shall be amended as follows: 
  
 The phrase “Large Scale Manufacturing Suite” found therein shall in each case be deleted and replaced by the phrase “***** *****
Manufacturing Suite.” 
  
 31.  Section 6.8 (“Supply
Failure”).  Section 6.8 shall be amended to read in its entirety as follows: 
  
 “If a Supply Deficiency arises such that LB is unable (or the Parties agree that there is no reasonable likelihood that LB will be able) to Deliver
to Alexion at least *** of the Batches agreed to be Delivered in any *** period, then such event shall constitute a Supply Failure.” 
  
 Sections 6.8.1, 6.8.2, and 6.8.3 shall remain as written in the Large-Scale Product Supply Agreement. 
  
 32.  Section 8.2.1 (“Function of Steering
Committee”).  Section 8.2.1 shall be amended as follows: 
  

	 	a.	the Phrase “Large Scale Manufacturing Suite” shall be deleted and replaced by the phrase “***** ***** Manufacturing Suite;” and 

 

	 	b.	the phrase “status of the construction and” shall be deleted. 

  
 33.  Section 11.1 (“Regulatory Support and Audits”).  In line 10 of Section 11.1, the sentence beginning with “In addition, LB
shall” and every following sentence in the Section shall be replaced with the following: 
  
 “In addition, LB shall allow, and the Price has been further calculated to include, 
  

	 	a.	“an Alexion employee or consultant located at the ***** ***** Manufacturing Suite (i.e., a man-in-plant) for a period of up to two (2) months prior to Commencement of
each Batch, to no longer than one (1) month past final release by LB for each Batch manufactured. 

  
  

 Page 6 of 12 

	 	b.	“Batch record audits of each Batch shall be permitted and copies of documentation can be provided upon request without additional cost to Alexion.”

  

	 	c.	“those costs incurred by LB in completion of the Pre-Approval Inspection (PAI) for the Product.” 

  
 34.  Section 11.4 (“Additional Audits”).  Section 11.4
shall be amended as follows: 
  
 The phrase “Large-Scale
Manufacturing Suite” found therein shall in each case be deleted and replaced by the phrase “***** ***** Manufacturing Suite.” 
  
 35.  Section 12.1 (“Request by Alexion”).  Section 12.1 shall be amended as follows: 
  
 The phrase “Large-Scale Manufacturing Suite” found therein shall
in each case be deleted and replaced by the phrase “***** *****   Manufacturing Suite.” 
  
 36.  Section 13.1.1 (“Price for Services”).  Section 13.1.1 shall be amended to read in its entirety as follows: 
  

	 	a.	“The Batch Price for the ***** Pre-Validation ***** is **********; the Batch Price for the ****** Pre-Validation ***** is **********.

  

	 	b.	“The Batch Price for **** *** Process Validation **** is ********** per Batch; and the Batch Price for the ***** and later Validation Batches, if any, is
**********. The aforementioned Batch Price shall be revised in the event that cycles are lost during processing of the Validation Batches that are solely attributable to LB execution of the Process. The Batch Price shall be revised for such
lost cycles by the Success Ratio as defined below: 

  

															
	 ******* *****
	 	=	 	******* * *******	 	×	 	* ********* *******	 	×	 	* ******* *******	 	 
	 	 	
	 	 	
	 	 	
	 	 
	 	 	******* * *****	 	 	* ********* *****	 	 	* ******** *****	 	 

  

	 	c.	“The Batch Price for Batches Commenced on or prior to December 31, 2008 (other than the * Batches referred to in clauses (a) and (b) above) shall be **********
per Batch subject to an annual PPI adjustment in accordance with Section 13.3.1. The aforementioned Batch Price shall be revised in the event that cycles are lost during processing of the Batch by the Success Ratio as defined below:”

  

															
	 ******* *****
	 	=	 	******* * *******	 	×	 	* ********* *******	 	×	 	* ******* *******	 	 
	 	 	
	 	 	
	 	 	
	 	 
	 	 	******* * *****	 	 	* ********* *****	 	 	* ******** *****	 	 

  
  

 Page 7 of 12 

 37.  Section 13.1.2 (“Price for Services”).  Section 13.1.2 shall be amended to read in its
entirety as follows: 
  
 “If Batches additional to the
Minimum Order of ****** **** covered by this Agreement are requested by Alexion, the Batch Price for the ************ and all Batches beyond shall be ********** subject to an annual PPI adjustment in accordance with Section
13.3.1. 
  
 38.  Section 13.1.3 (“Price for
Services”).  Section 13.1.3 shall be deleted in its entirety and the words “This Clause left intentionally blank” shall be inserted in its stead. 
  
 39.  Section 13.2 (“Minimum Order Requirements”).  Section 13.2 shall be ****** **** Batches
ordered, other than **** *** Pre-Validation and **** *** Validation Batches. 
  
 40.  Section 13.3.1 (“Batch Price Adjustments”).  Section 13.3.1 shall be amended as follows: 
  

	 	a.	In the first line the words “on the suite Use Commencement Date and thereafter effective” shall be removed; and 

  

	 	b.	the date “December 31, 2001” found in the fourth line shall be deleted and replaced by the date “December 31, 2006.” 

  
 41.  Section 13.3.2 (“Batch Price
Adjustments”).  Section 13.3.2 shall be deleted in its entirety and the words “this clause left intentionally blank” shall be inserted in its stead. 
  
 42.  Section 13.3.3 (“Batch Price Adjustments”).  Section 13.3.3 shall be deleted in its entirety and
the words “This Clause left intentionally blank” shall be inserted in its stead. 
  
 43.  Section 13.7 (“Raw Materials Fee”).  Section 13.7 shall be deleted in its entirety and the words “This Clause left intentionally blank” shall be inserted in its
stead. 
  
 44.  Section 13.8 (“Payment of Raw Materials
Fee”).  Section 13.8 shall be deleted in its entirety and the words “This Clause left intentionally blank” shall be inserted in its stead. 
  
 45.  Section 13.9 (“Price for Undelivered Large-Scale Product”).  All provisions of Section 13.9 other
than the first sentence and last sentence thereof shall be deleted. 
  
 46.  Section 13.10 (“Consistency Batches”).  Section 13.10 shall be amended to read in its entirety as follows: 
  

“Validation Batches. In respect of each Validation Batch which is manufactured by LB but not Delivered to Alexion, or that otherwise does not
satisfy the Specifications, Alexion shall pay *** of the Batch Price; 
  
  

 Page 8 of 12 

 provided, however, that Alexion shall not pay such amounts in respect of Batches that are not Delivered
or do not satisfy the Specifications due to the breach, gross negligence, or willful misconduct of LB, and provided further that the Batch Price invoiced for any Validation Batch that is not Delivered due to a failure of the Batch in a reactor prior
to the first seed reactor of the Fermenter Train shall be credited towards the Batch Price due for the replacement Validation Batch thereof. Notwithstanding the foregoing, in the event that LB has conducted a number of runs of the Large-Scale
Process that is equal to ***** ***** the number of Validation Batches required by the U.S. FDA and in the event that pursuant to Section 6.3 Alexion requests LB to conduct additional runs of the Large-Scale Process, then Alexion shall pay
**** of the Batch Price in respect of each additional Validation Batch which is manufactured by LB but not Delivered to Alexion, or that otherwise does not satisfy the Specifications; provided, however, that Alexion shall not pay such amounts
in respect of Batches that are not Delivered or do not satisfy the Specifications due to the breach, gross negligence, or willful misconduct of LB, and provided further that the Batch Price invoiced for any Validation Batch that is not Delivered due
to a failure of the Batch in a reactor prior to the first seed reactor of the Fermenter Train shall be credited towards the Batch Price due for the replacement Validation Batch thereof. 
  
 47.  Section 13.15 (“Advance”).  Section 13.15 shall be amended to read in its entirety as follows:

  
 “Alexion will pay to LB the sum of five million dollars
($5,000,000) on or before August 1, 2004, which sum is the Advance hereunder. For the avoidance of doubt, Alexion is entitled to utilize $1,500,000 as a credit against such Advance in accordance with Section 1 of this Amendment 1.” 

 
 48.  Section 13.16 (“$10 Million Sales
Milestone”).  Section 13.16 shall be deleted in its entirety and the words “This Clause left intentionally blank” shall be inserted in its stead. 
  
 49.  Section 13.17 (“$15 Million Yield Milestone”).  Section 13.17 shall be deleted in its entirety and
the words “This Clause left intentionally blank” shall be inserted in its stead. 
  
 50.  Section 18.1 (“Termination Without Cause”).  Section 18.1 shall remain as written in the Agreement, but Subsections 18.1.1, 18.1.2 and 18.1.3 shall be deleted in their
entirety and replaced with the following: 
  
 “18.1.1. If
Alexion terminates this Agreement pursuant to this Section, by notice delivered on or prior to 30th September 2006, Alexion will pay to LB the Fee identified in Table-1 below that is consistent with the Forecast Order in Attachment 1. LB may retain
amounts, if any, paid under this 
  
  

 Page 9 of 12 

 
provision in full, with no obligation to use good faith efforts to reduce such amounts through mitigation.” 
  
 Table-1 
  

			
	 Notice of Termination

	  	 Termination Payment

	 Q2 2004
	  	$*
	 Q3 2004
	  	$*
	 Q4 2004
	  	$*
	 Q1 2005
	  	$*
	 Q2 2005
	  	$*
	 Q3 2005
	  	$*
	 Q4 2005
	  	$*
	 Q1 2006
	  	$*
	 Q2 2006
	  	$*
	 Q3 2006
	  	$*

  
 18.1.2. If Alexion
terminates this Agreement pursuant to this Section 18.1.2 on or after the 1st October 2006, Alexion will pay *** of
the Batch Price for all Batches scheduled for start of manufacture within six (6) months of such notice, and *** of the Batch Price for all Batches scheduled for start of manufacture between six (6) months and one (1) year of such notice. LB may
retain any amount paid under this provision in full, with no obligation to use good faith efforts to reduce such amounts through mitigation. 
  
 51.  Section 18.2 (“Decrease in Minimum Order”).  Section 18.2 shall be amended to read in its entirety as follows: 
  
 “Decrease in Minimum Order. Alexion may order fewer than ***** ****
Batches during the initial term. In such event, Alexion will pay Lonza a percentage of the then current Batch Price for each Batch fewer than ***** **** as calculated by the following method: 
  

			
	 Batches Below
 Minimum

	  	Cancellation Fee

	   1-6  
	  	****
	   7-12
	  	****
	 13-20
	  	****

  
  

 Page 10 of 12 

 By way of example, if Alexion ordered ** Batches then the cancellation fee is calculated as follows:
******** * ************ **********************. Such amounts will be paid on the final day of the initial Term, and Lonza will have no obligation to use good faith efforts to reduce such amounts through mitigation.” 
  
 52.  This Amendment 1 constitutes the full and entire understanding and agreement
between the Parties with regard to the subjects of this Amendment 1 and supersedes any prior understandings, agreements, amendments or representations by or between the Parties, written, or oral, to the extent they relate in any way to the subjects
of this Amendment 1. 
  
 53.  Any Section in the Agreement not modified
by this Amendment 1 shall remain unchanged. 
  
 54.  If there are any
conflicts between the Agreement and this Amendment 1 the terms of this Amendment 1 shall control. 
  
 IN WITNESS WHEREOF, the parties hereto have executed this Amendment 1 to be effective on the date first set forth above (the Effective Date).

  

					
	Lonza	    	 	 	Alexion
			
	 /s/    G. F. Klement
	    	 	 	/s/    David Keiser
	
	 	 	 	

	 Signature
	    	 	 	Signature
			
	 G. F. Klement, Chief Operating Officer
	    	 	 	David Keiser, President & Chief Executive Officer
	
	 	 	 	

	 Printed Name and Title
	    	 	 	Printed Name and Title

  
  

 Page 11 of 12 

 ATTACHMENT 1 
  
 Forecast Order for Eculizumab Production 
  

					
	 Batch

	 	 OOF

	 	 Release

	 *** **
	 	** ** ***** ** **** **	 	*** **
	 *** **
	 	*** **	 	*** **
	 *** **
	 	** *** **	 	*** **
	 ** **
	 	** *** **	 	*** **
	 ** **
	 	** *** **	 	*** **
	 ** **
	 	** *** **	 	*** **
	 ** **
	 	** *** **	 	*** **
	 * *******
	 	** *** ****	 	** ****
	 * *******
	 	** *** ****	 	** ****
	 * *******
	 	** *** ****	 	***** ****

  

	1.	The above Forecast Order must be confirmed by Parties as a Binding Order at a minimum of ******** **** months from start date (OOF) at which time the Forecast Order shall become a
Binding Order. 

  

	2.	Lonza shall provide test results (other than viral testing) from the ***** batch to Customer a minimum of two (2) weeks prior to the OOF date of ***** 

  
  

 Page 12 of 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]